Unity Biotechnology, Inc.
NASDAQ:UBX
Overview | Financials
Company Name | Unity Biotechnology, Inc. |
Symbol | UBX |
Currency | USD |
Price | 1.26 |
Market Cap | 21,227,976 |
Dividend Yield | 0% |
52-week-range | 1.22 - 2.26 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Anirvan Ghosh Ph.D. |
Website | https://unitybiotechnology.com |
An error occurred while fetching data.
About Unity Biotechnology, Inc.
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD